Related Experiment Video
Updated: May 29, 2026
Characterization of Intra-Cartilage Transport Properties of Cationic Peptide Carriers
Published on: August 10, 2020
Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy
Xavier Chevalier1, Thierry Conrozier, Pascal Richette
1Department of Rheumatology, University of Paris XII, Henri Mondor Hospital, Bd de Lattre de Tassigny, Creteil 94010, France. xavier.chevalier@hmn.aphp.fr
Abstract:
Blocking IL-1 in patients with knee osteoarthritis is an attractive strategy. Cohen and colleagues report a randomised, placebo-controlled, multiple-dose trial using a monoclonal antibody blocking IL-1 type 1 receptor. They failed to show any positive results in terms of evolution of pain for up to 12 weeks, in line with the former trials using intraarticular injections of IL-1 receptor antagonist. A trend was observed, however, in a subgroup of patients with high level of pain at baseline. Although these data may suggest cessation of IL-1 therapy in osteoarthritis, other methods such as limited intraarticular anti-IL-1 delivery should still be considered.
Insights
Blocking interleukin-1 (IL-1) did not reduce knee osteoarthritis pain in a 12-week trial. However, a trend suggested potential benefits in patients with severe baseline pain, warranting further investigation into targeted IL-1 inhibition.
Area of Science:
- Rheumatology
- Immunology
- Osteoarthritis Research
Background:
- Interleukin-1 (IL-1) is implicated in the pathogenesis of knee osteoarthritis.
- Targeting IL-1 is a potential therapeutic strategy for osteoarthritis pain management.
Purpose of the Study:
- To evaluate the efficacy of a monoclonal antibody blocking the IL-1 type 1 receptor in patients with knee osteoarthritis.
- To assess the impact of IL-1 blockade on pain evolution over 12 weeks.
Main Methods:
- A randomized, placebo-controlled, multiple-dose trial was conducted.
- Participants received either the IL-1 blocking antibody or a placebo.
- Pain levels were assessed up to 12 weeks post-treatment.
Main Results:
- The study failed to demonstrate a significant reduction in knee osteoarthritis pain compared to placebo over 12 weeks.
- A trend towards pain improvement was observed in a subgroup of patients with high baseline pain levels.
- Results align with previous trials using intraarticular IL-1 receptor antagonists.
Conclusions:
- Systemic IL-1 blockade may not be effective for overall knee osteoarthritis pain relief.
- Targeted or limited intraarticular delivery of anti-IL-1 agents warrants further consideration for specific patient subgroups.
- Further research is needed to explore alternative IL-1 inhibition strategies in osteoarthritis.
